Akebia Therapeutics Inc
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialy… Read more
Akebia Therapeutics Inc (AX9) - Total Assets
Latest total assets as of September 2025: €364.15 Million EUR
Based on the latest financial reports, Akebia Therapeutics Inc (AX9) holds total assets worth €364.15 Million EUR as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Akebia Therapeutics Inc - Total Assets Trend (2015–2024)
This chart illustrates how Akebia Therapeutics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Akebia Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Akebia Therapeutics Inc's total assets of €364.15 Million consist of 51.6% current assets and 48.4% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 23.5% |
| Accounts Receivable | €34.37 Million | 15.6% |
| Inventory | €16.24 Million | 7.4% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €59.04 Million | 26.8% |
Asset Composition Trend (2015–2024)
This chart illustrates how Akebia Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Akebia Therapeutics Inc's current assets represent 51.6% of total assets in 2024, a decrease from 98.7% in 2015.
- Cash Position: Cash and equivalents constituted 23.5% of total assets in 2024, down from 34.8% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 26.0% of total assets, an increase from 0.0% in 2015.
- Asset Diversification: The largest asset category is goodwill at 26.8% of total assets.
Akebia Therapeutics Inc Competitors by Total Assets
Key competitors of Akebia Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Akebia Therapeutics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Akebia Therapeutics Inc generates 0.73x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Akebia Therapeutics Inc is currently not profitable relative to its asset base.
Akebia Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.94 | 1.52 | 1.98 |
| Quick Ratio | 1.80 | 1.21 | 1.66 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €124.96 Million | € 34.41 Million | € 184.29 Million |
Akebia Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Akebia Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.64 |
| Latest Market Cap to Assets Ratio | 1.28 |
| Asset Growth Rate (YoY) | -8.7% |
| Total Assets | €220.67 Million |
| Market Capitalization | $283.56 Million USD |
Valuation Analysis
Above Book Valuation: The market values Akebia Therapeutics Inc's assets above their book value (1.28 x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Akebia Therapeutics Inc's assets decreased by 8.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Akebia Therapeutics Inc (2015–2024)
The table below shows the annual total assets of Akebia Therapeutics Inc from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €220.67 Million | -8.70% |
| 2023-12-31 | €241.70 Million | -31.30% |
| 2022-12-31 | €351.83 Million | -33.05% |
| 2021-12-31 | €525.55 Million | -18.41% |
| 2020-12-31 | €644.14 Million | -16.48% |
| 2019-12-31 | €771.20 Million | -22.61% |
| 2018-12-31 | €996.54 Million | +173.59% |
| 2017-12-31 | €364.25 Million | +21.33% |
| 2016-12-31 | €300.22 Million | +110.03% |
| 2015-12-31 | €142.94 Million | -- |